RAFAEL HOLDINGS, INC. Noninterest Expense Related to Performance Fees
RAFAEL HOLDINGS, INC. (RFL) had Noninterest Expense Related to Performance Fees of $10.50 million as of 2023-06-02, per its 10-Q filed 2026-06-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:NoninterestExpenseRelatedToPerformanceFees · last filed 2026-06-11
- 2023-06-02: Noninterest Expense Related to Performance Fees $10.50M.
| Period end | Noninterest Expense Related to Performance Fees |
|---|---|
| 2023-06-02 | $10.50M 10-Q · filed 2026-06-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |